TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05787158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy techniques
Description: Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy techniques
Description: Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
Study: NCT05098106

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy, blood sampling; testing.
Description: BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy, blood sampling; testing.
Description: BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
Study: NCT05477147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
Study: NCT05761574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Naproxen Sodium will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06461819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
Description: this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
Study: NCT05164432

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Women will have an MRI scan during pregnancy to evaluate the fetus and placenta

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Description: Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
Study: NCT06183814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
Study: NCT05603832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F14
Description: 625 mg intra-articular sustained-release celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 % Bupivacaine HCl
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 % Bupivacaine HCl
Description: Local anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Analgesic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Description: Muscle relaxant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methocarbamol
Description: Muscle relaxant
Study: NCT06333834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional scorpion antivenom regimen
Description: All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serial dose of scorpion antivenom regimen
Description: All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
Study: NCT04670003

Intervention type: OTHER
Intervention: users
Description: Data of users of the web-application
Study: NCT05147727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole、Famitinib
Description: Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
Study: NCT04570813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artistic activies
Description: 12 workshops of artictic activities during 12 weeks
Study: NCT06321458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention
Description: Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT06093737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE: Communities Organizing for Power through Empathy
Description: A three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPE: Communities Organizing for Power through Empathy
Description: A three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
Study: NCT06164847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AERO Program
Description: HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
Study: NCT06587412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial shock waves treatment
Description: Subjects in this group will receive radial shock waves

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Shock Waves treatment
Description: Subjects in this group will receive focal shock waves

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: shock waves placebo treatment
Description: Subjects in this group will receive a shock waves placebo treatment with very low energy settings
Study: NCT06110806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBIE
Description: MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
Study: NCT06600152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAP Wound Matrix
Description: The MAP Wound Matrix is indicated for the management of full thickness wounds, including surgical sites, donor skin graft sites, wound dehiscence, lacerations, and draining wounds. The application of MAP Wound Matrix will occur immediately after Mohs surgery once hemostasis has been achieved

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuoDerm
Description: DuoDerm is a hydrocolloid dressing will be topically applied to the wound immediately following Mohs surgery according to the manufacturer\&#39;s instructions.
Study: NCT06662409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-based healing meditation (NBHM) intervention
Description: 6 nature-based healing meditation (NBHM) auditory modules available via the study website to facilitate bereavement (grief) recovery and assessed on parameters of directed attention, grief, and QOL (including parameters of depression/anxiety)
Study: NCT06665204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline-adherent Care
Description: Clinical examination procedures will be used to identify all appropriate impairment subcategories (Overuse/Overload without Other Impairment, PFP with Movement Coordination Deficits, PFP with Muscle Performance Deficits, PFP with Mobility Impairments) and create a subcategory-specific or multimodal (for patients classified to \>1 subcategory) plan of care. Research physical therapists will target all applicable impairment subcategories using the corresponding CPG-recommended interventions, all of which are recommended for use as part of standard-of-care physical therapy practice. The duration and length of care will not be prespecified or standardized across participants to allow flexibility pending participant's care needs and schedule (e.g., vacation, short-term TDY status); however, research PTs will be trained to target providing no more than 10-12 visits over no more than 6-8 weeks to promote generalizability of the CPG-adherent intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Standard-of-care physical therapy will be provided by a licensed outpatient staff physical therapist who is not associated with the research team. The outpatient physical therapists will not treat participants in the CPG-adherent group and will be free to treat their participants based on their current personal and organizational clinical practice standards. The research team will neither influence nor restrict the evaluations conducted or interventions provided.
Study: NCT06665620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ViraBrite nudges
Description: Each day, participants will receive prompts via smartphone notifications that encourage them to access the ViraBrite app and utilize suicide safety planning skills.
Study: NCT06666075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital and Interactive Reminiscence
Description: The intervention for the experimental group aims to enhance the psychological well-being of institutionalized seniors with Alzheimer's through a digital and interactive reminiscence therapy program. It begins with selecting participants based on specific inclusion and exclusion criteria, followed by developing personalized digital profiles that include photographs, music, videos, and life anecdotes to evoke emotional memories. Care staff receive training in using the digital software and reminiscence techniques. The core intervention consists of digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each, featuring multimedia content to encourage discussion and memory sharing. Interactive activities foster active participation, with facilitators promoting emotional expression and connection among participants, creating a supportive environment that stimulates cognitive function and reduces isolation.
Study: NCT06665152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProTaper File System
Description: A rotary file system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne File System
Description: A reciprocating file system
Study: NCT06668454

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
Description: Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
Study: NCT06395506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
Study: NCT06667752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Antibacterial Wound Dressing
Description: For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag+ Extra
Description: For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
Study: NCT06088004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO2011 Injection
Description: Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO2011 Injection
Description: Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Anti-PD-1 antibody
Study: NCT06666088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation and Strength training
Description: The experimental group will participate in a 12-week program to enhance cognitive functions and physical strength through twice-weekly sessions of 45 minutes to 1 hour. Cognitive stimulation activities will improve memory, attention, processing speed, and executive functions through memory games, recall exercises, and tasks that promote focus and quick thinking. Each session will be led by a neuropsychology or occupational therapy professional who will tailor activities to individual needs.~Strength training will also occur twice a week, focusing on exercises that strengthen major muscle groups, improve balance, and enhance coordination. Participants will use light weights, resistance bands, and bodyweight exercises, with modifications based on their physical levels. A specialized trainer will supervise the program, progressively adjusting exercise intensity to ensure safety and optimize benefits.
Study: NCT06667388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group A
Description: each participant of this groups will receive 4 weeks of FWT and 4 weeks of BWT (the training order of A group will FWT and BWT), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Grojup B
Description: each participant of B group will receive 4 weeks of BWT and 4 weeks of FWT (the training order of group B will be BWT and FWT, opposite to group A), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
Study: NCT06667531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
Study: NCT06667492

Intervention type: DEVICE
Intervention: Traction Dynamometry
Description: K-Pull dynamometer (Model MP.09.02.FN, Kinvent, Montpellier, France) is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions. This instrument will be used to evaluate isometric activity (maximum and average torque values) of the hip and knee flexors and extensors at specific joint angles.
Study: NCT06666348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
Study: NCT06667024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Hyperbaric bupivacaine
Description: Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
Study: NCT06094413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Training Intervention
Description: The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
Study: NCT06621745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Intervention App
Description: The GIA app, an iOS application designed for this study, is based on effective gratitude interventions and tailored for youth. Access required a unique login. It features five exercises: a journal, photo book, imagine exercise, speech exercise, and meditation. The journal encourages daily entries. The photo book involves uploading photos of things users are grateful for, promoting mindfulness. The imagine exercise reflects on gratitude, while the speech exercise records users' gratitude. The meditation exercise enhances well-being. During the three-week study, daily notifications prompted exercise completion. The app, green and white with a flower-heart icon, offers email support for technical issues.
Study: NCT06618079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-565-A, HUC2-565-A and HUC2-565-B
Description: Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-565-B, HUC2-565-A and HUC2-565-B
Description: Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.